Volume 164, Issue s1 pp. 1-14
CASE SERIES

Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course

R.B. Warren

R.B. Warren

Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK

Search for more papers by this author
C.E. Kleyn

C.E. Kleyn

Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK

Search for more papers by this author
W.P. Gulliver

W.P. Gulliver

Division of Dermatology, Memorial University of Newfoundland, St John’s, Newfoundland, Canada

Search for more papers by this author
First published: 07 April 2011
Citations: 112
Richard Warren.
E-mail:
[email protected]

Funding sources
Financial support for writing assistance and publication of this supplement was supplied by Abbott Laboratories.

Conflicts of interest
R.B.W. has acted as a consultant and/or speaker for Abbott, Janssen Cilag, Leo Pharma, Merck-Serono, Pfizer, Schering Plough and Wyeth. C.E.K. has acted as a consultant and/or speaker for Abbott, GlaxoSmithKline, Janssen Cilag, Leo Pharma, Schering Plough and Wyeth and received research funding (unrestricted educational grants) from Merck-Serono and Janssen Cilag. W.P.G. has acted as an investigator, speaker and advisor and has received research funding from Abbott, and has acted as an investigator, speaker and advisor for Merck.

Summary

Psoriasis is associated with significant physical, psychological, social and economic burden, the cumulative effect of which may result in failure to achieve ‘full life potential’ in some patients, termed ‘cumulative life course impairment’ (CLCI). In this concept, the burden of stigmatization, and physical and psychological comorbidities (risk factors for cumulative impairment) and coping strategies and external factors (having potential moderating effects), interact to cause lifetime impairment. Components of CLCI are supported by cross-sectional data; however, the cumulative nature of impairment in patients with psoriasis is not yet established. Nonetheless, CLCI makes intuitive sense to many dermatologists who recognize the cumulative impact of psoriasis on the lives of some patients. This supplement explores the causes and mechanisms of CLCI qualitatively by presenting cases which are representative of typical patients with moderate-to-severe psoriasis. These cases demonstrate the effect of psoriasis in influencing major life-changing decisions and altering the course of patients’ lives, preventing patients from attaining their life goals, pursuing their chosen career, gaining a desired educational level, developing social relationships, gaining full pleasure from family life or having children. All these patients believe that their lives would have taken a different course had they not had psoriasis. Additional research to determine how CLCI occurs and to identify the risk factors for cumulative impairment is required. Understanding the key risk factors for CLCI may help physicians identify patients who are more vulnerable to the cumulative impact of psoriasis, resulting in more appropriate treatment decisions earlier in the disease course.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.